Damora Therapeutics, Inc. 8-K

What Happened

• Damora Therapeutics, Inc. (DMRA) filed an 8-K on April 20, 2026 reporting that its Audit Committee dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the company’s independent registered public accounting firm, effective April 17, 2026. EY Denmark had served as the company’s auditor since 2019.
• EY Denmark’s audit reports on Damora’s consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 contained no adverse or qualified opinions; the 2024 report did include an explanatory paragraph about the company’s ability to continue as a going concern.

Key Details

• Dismissal date: April 17, 2026 (8-K filed April 20, 2026).
• EY served as Damora’s independent auditor since 2019.
• EY’s reports for 2024 and 2025 were unqualified (no adverse opinion); 2024 report included a going concern explanatory paragraph.
• The company reported no disagreements or “reportable events” with EY during the fiscal years ended Dec 31, 2025 and 2024 or the interim period Jan 1–Apr 17, 2026.
• The filing includes EY’s letter dated April 17, 2026 (Exhibit 16.1).

Why It Matters

• A change of independent auditor is a material governance event investors watch because it can affect confidence in financial reporting and trigger review of accounting controls. In this case, the company says there were no disagreements with EY and no reportable events, which suggests the change was not driven by a dispute over accounting or audit matters.
• The prior auditor’s 2024 going concern explanatory paragraph remains a notable fact for investors: it signals that the company previously flagged uncertainty about its ability to continue operations without additional financing or other actions. There is no indication in this filing that the company’s financial statements will be restated or that EY raised audit-quality issues.